Intra-Cellular Therapies Q2 2024 GAAP EPS $(0.16) Beats $(0.20) Estimate, Sales $161.400M Beat $157.880M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies (NASDAQ:ITCI) reported Q2 2024 GAAP EPS of $(0.16), beating the estimate of $(0.20). Sales were $161.4M, surpassing the $157.88M estimate and marking a 45.68% increase from the same period last year.
August 07, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.16) beating estimates by 20% and sales of $161.4M surpassing estimates by 2.23%. Sales also increased by 45.68% YoY.
The better-than-expected earnings and significant YoY sales growth are likely to positively impact ITCI's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100